Karyopharm to Participate at the Piper Sandler 36th Annual Healthcare Conference
Karyopharm to Participate at the Piper Sandler 36th Annual Healthcare Conference
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit , and follow us on LinkedIn and on X at @Karyopharm.NEWTON, Mass., Nov. 25, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at the Piper Sandler 36th Annual Healthcare Conference in a fireside chat on Tuesday, December 3 at 11:30 a.m. ET in New York, NY.
馬薩諸塞州牛頓，2024年11月25日 /PRNewswire/ — 開創新型癌症療法的商業階段製藥公司Karyopharm Therapeutics Inc.（納斯達克股票代碼：KPTI）今天宣佈，該公司的高級管理團隊將於美國東部時間12月3日星期二上午11點30分在紐約州紐約參加派珀·桑德勒第36屆年度醫療保健會議，進行爐邊談話。
A live webcast of the fireside chat can be accessed under "Events & Presentations" in the Investor section of the Company's website, , and will be available for replay following the event.
爐邊談話的網絡直播可以在公司網站 「投資者」 部分的 「活動與演講」 下觀看，活動結束後將可供重播。
About Karyopharm Therapeutics
關於 Karyopharm Therapeu
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit , and follow us on LinkedIn and on X at @Karyopharm.
Karyopharm Therapeutics Inc.（納斯達克股票代碼：KPTI）是一家處於商業階段的製藥公司，其致力於開創新型癌症療法，這源於對癌症患者非凡力量和勇氣的信念。自成立以來，Karyopharm一直是解決核出口失調（腫瘤發生的基本機制）的口服化合物的行業領導者。Karyopharm的主要化合物和同類首創的口服出口素1（XPO1）抑制劑XPOVIO（selinexor）已在美國獲得批准，並由該公司在三種腫瘤適應症中上市。它還在越來越多的前美國領土和國家，包括歐洲和英國（如NEXPOVIO）和中國，以各種方式獲得了監管部門的批准。Karyopharm擁有針對多種高需求癌症的適應症的重點產品線，包括多發性骨髓瘤、子宮內膜癌、骨髓纖維化和瀰漫性大b細胞淋巴瘤（DLBCL）。如需了解有關我們的員工、科學和管道的更多信息，請訪問 ，然後在 LinkedIn 和 X 上關注我們，網址爲 @Karyopharm。
XPOVIO and NEXPOVIO are registered trademarks of Karyopharm Therapeutics Inc. Any other trademarks referred to in this release are the property of their respective owners.
XPOVIO和NEXPOVIO是Karyopharm Therapeutics Inc.的註冊商標。本新聞稿中提及的任何其他商標均爲其各自所有者的財產。
SOURCE Karyopharm Therapeutics Inc.
來源 Karyopharm Therapeutics Inc.
